pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 1·1 min read
save

Alcohol industry fights declining demand by intensifying behind-the-scenes lobbying, says STAT+

Jul 1, 2026·read at STAT ↗Negative

Recent data show that U.S. alcohol consumption is falling, creating a challenging market for producers.

In response, companies have stepped up lobbying efforts aimed at lawmakers, nonprofit events, and even social media platforms such as TikTok to shape public opinion and oppose new restrictions.

The article reports that these tactics are proving effective, with the industry winning battles against proposed limits despite the headwinds.

It also highlights a controversy involving Len Lichtenfeld and the American Cancer Society, revealing financial ties between the society and the alcohol industry that were previously downplayed.

Overall, the piece suggests the alcohol sector is leveraging its influence more creatively as demand wanes.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes”

read at STAT ↗
766 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ELI LILLY COEli Lilly and CoLILLYNOVONovo Nordisk Inc
drugs
Obesity
topics
Oncology5Atopic DermatitisBispecific AntibodyObesity

related stories

  • Aug 19Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreBioSpace
  • Jul 16Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBioSpace
  • Jun 30STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo NordiskSTAT
  • Jun 295 takeaways from STAT’s investigation into microhospital operator Nutex HealthSTAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech